[Asia Economy Reporter Ji Yeon-jin] Alteogen announced on the 16th that the Ministry of Food and Drug Safety approved the Phase 1 clinical trial plan to evaluate the safety, tolerability, and pharmacokinetic characteristics of 'ALT-BB4 (Terzyme, recombinant hyaluronidase)' in healthy adults.



This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing